Kyntra Bio appeals Nasdaq delisting determination

The hearing request keeps the common stock listed and trading while the Nasdaq panel reviews the staff’s delisting determination.

Rhea-AI Filing Summary

Kyntra Bio, Inc. received a Nasdaq staff determination to delist its common stock after the company had not yet demonstrated compliance with a continued-listing requirement as of September 29, 2026. Kyntra Bio requested a hearing to seek additional time to regain compliance. The request stays the suspension of its securities and the filing of a Form 25-NSE pending the Nasdaq Hearings Panel’s written decision. The stock remains listed and trading on the Nasdaq Global Select Market while the Panel reviews the determination; an extension could be up to 180 days.

Kyntra Bio had previously disclosed that it did not meet Nasdaq’s total-asset and total-revenue standard or the alternative stockholders’ equity or market-value standards. The company is preparing a compliance plan, but said there can be no assurance the Panel will grant additional time or that it will regain compliance during any extension.

0 points · 0 major

NegativeiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 1 point

How the balance works

Positive

• None.

Negative

• Major pointNasdaq staff determined to delist Kyntra Bio after it had not demonstrated compliance by September 29, 2026.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

Key Figures

Total assets threshold: At least $50 million Total revenue threshold: At least $50 million Potential extension period: Up to 180 days +2 more

5 metrics

Total assets threshold At least $50 million Nasdaq continued-listing test

Total revenue threshold At least $50 million Nasdaq continued-listing test

Potential extension period Up to 180 days From the Staff delisting determination

Compliance deadline September 29, 2026 Date by which the company had not yet demonstrated compliance

Earlier Nasdaq notice April 2, 2026 Date of notice of continued-listing noncompliance

Key Terms

Nasdaq Hearings Panel, Form 25-NSE, continued listing requirements

3 terms

Nasdaq Hearings Panel regulatory

"hearing before a Nasdaq Hearings Panel"

A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.

Form 25-NSE regulatory

"filing of a Form 25-NSE"

Form 25‑NSE is an official filing used to notify the stock exchange that a company’s securities are being removed from trading on that exchange, similar to handing in a key when a shop closes. Investors care because removal ends public trading on that venue, often cutting liquidity and making it harder to buy or sell shares, which can affect a stock’s price and how quickly investors can access cash or exit positions.

continued listing requirements regulatory

"Nasdaq’s continued listing requirements"

Rules a stock exchange sets that a publicly traded company must keep meeting to stay listed and tradable on that exchange, such as minimum share price, market value, timely financial reports, and basic governance practices. Like a club’s membership rules, they matter because falling short can lead to warnings, penalties or removal from the exchange, which can cut liquidity, hurt share value and increase the risk for investors.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Nasdaq financial test did Kyntra Bio fail for KYNB?

Nasdaq’s test requires total assets and total revenue of at least $50 million each for the most recently completed fiscal year or two of the three most recently completed fiscal years. Kyntra Bio also did not satisfy the alternative stockholders’ equity or market value of listed securities standards.

Will KYNB keep trading while Nasdaq reviews the appeal?

The company’s hearing request stays the suspension of its securities and the filing of a Form 25-NSE pending the Panel’s written decision. Its common stock will remain listed and continue to trade on the Nasdaq Global Select Market under KYNB pending that decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/06/2026 - 04:05 PM Accepted by SEC EDGAR 10/06/2026 - 04:05 PM Learn about SEC filing dates

false000092129900009212992026-09-302026-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 30, 2026

KYNTRA BIO, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-36740	77-0357827
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
350 Bay Street Suite 100 #6009
San Francisco, California				94133
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 415 978-1200

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		KYNB		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On September 30, 2026, Kyntra Bio, Inc. (the “Company” or “Kyntra Bio”) received a determination letter (“Determination”) from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had not yet demonstrated compliance with Nasdaq Listing Rule 5450(b) as of the September 29, 2026 deadline and that, as a result, the Staff had determined to delist the Company’s common stock from the Nasdaq Global Select Market.

The Company has timely requested a hearing before a Nasdaq Hearings Panel (the “Panel”) to review the Staff Determination and to seek additional time to regain compliance with Nasdaq’s continued listing requirements. The hearing request stays the suspension of the Company’s securities and the filing of a Form 25-NSE pending the Panel’s written decision. An extension period could be up to 180 days from the Staff delisting Determination pursuant to Listing Rule 5815(c)(1)(A). Accordingly, the Company’s common stock will remain listed and continue to trade on the Nasdaq Global Select Market under the symbol “KYNB” pending the Panel’s decision.

As previously disclosed, on April 2, 2026, Kyntra Bio received notice from the Staff of Nasdaq that the Company was not in compliance with the continued listing requirements of Nasdaq Listing Rule 5450(b)(3)(A), which requires total assets and total revenue of at least $50 million each for the most recently completed fiscal year or two of the three most recently completed fiscal years. The Company also did not satisfy the alternative stockholders’ equity or market value of listed securities standards under Nasdaq Listing Rule 5450(b).

The Company is actively preparing a compliance plan for the Panel; however, there can be no assurance that the Panel will grant the Company’s request for continued listing or that the Company will be able to regain compliance with the applicable continued listing requirements within any extension period that may be granted by the Panel.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			KYNTRA BIO, INC.
Date:	October 6, 2026	By:	/s/ John Alden
			John Alden General Counsel

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 24.3 KB